Journal article
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
Kenneth F Bradstock, Emma Link, Juliana Di Iulio, Jeff Szer, Paula Marlton, Andrew H Wei, Arno Enno, Anthony Schwarer, Ian D Lewis, James D'Rozario, Luke Coyle, Gavin Cull, Phillip Campbell, Michael F Leahy, Uwe Hahn, Paul Cannell, Campbell Tiley, Ray M Lowenthal, John Moore, Kimberly Cartwright Show all
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017
Abstract
Purpose Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown to improve remission rates and survival. We hypothesized that improvements in outcomes in adult AML may be further achieved by increased anthracycline dose during consolidation therapy. Patients and Methods Patients with AML in complete remission after induction therapy were randomly assigned to receive two cycles of consolidation therapy with cytarabine 100 mg/m2 daily for 5 days, etoposide 75 mg/m2 daily for 5 days, and idarubicin 9 mg/m2 daily for either 2 or 3 days (standard and intensive arms, respectively). The primary end point was leukemia-free survival (LF..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Funding Acknowledgements
Supported by the National Health and Medical Research Council of Australia (NHMRC Project Grant 302133) and by unrestricted grants from Pharmacia Australia (now Pfizer Australia) and Amgen Australia.